CONMED Statistics
Total Valuation
CONMED has a market cap or net worth of $1.89 billion. The enterprise value is $2.81 billion.
| Market Cap | 1.89B |
| Enterprise Value | 2.81B |
Important Dates
The last earnings date was Wednesday, February 5, 2025, after market close.
| Earnings Date | Feb 5, 2025 |
| Ex-Dividend Date | Dec 20, 2024 |
Share Statistics
CONMED has 30.91 million shares outstanding. The number of shares has decreased by -1.26% in one year.
| Current Share Class | 30.91M |
| Shares Outstanding | 30.91M |
| Shares Change (YoY) | -1.26% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 0.81% |
| Owned by Institutions (%) | 112.58% |
| Float | 30.65M |
Valuation Ratios
The trailing PE ratio is 14.38 and the forward PE ratio is 14.09. CONMED's PEG ratio is 1.27.
| PE Ratio | 14.38 |
| Forward PE | 14.09 |
| PS Ratio | 1.44 |
| Forward PS | 1.36 |
| PB Ratio | 1.96 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 12.28 |
| P/OCF Ratio | 11.32 |
| PEG Ratio | 1.27 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.24, with an EV/FCF ratio of 18.27.
| EV / Earnings | 21.24 |
| EV / Sales | 2.15 |
| EV / EBITDA | 12.24 |
| EV / EBIT | 17.66 |
| EV / FCF | 18.27 |
Financial Position
The company has a current ratio of 2.30, with a Debt / Equity ratio of 0.98.
| Current Ratio | 2.30 |
| Quick Ratio | 0.94 |
| Debt / Equity | 0.98 |
| Debt / EBITDA | 3.96 |
| Debt / FCF | 6.16 |
| Interest Coverage | 4.27 |
Financial Efficiency
Return on equity (ROE) is 14.74% and return on invested capital (ROIC) is 5.33%.
| Return on Equity (ROE) | 14.74% |
| Return on Assets (ROA) | 4.32% |
| Return on Invested Capital (ROIC) | 5.33% |
| Return on Capital Employed (ROCE) | 7.85% |
| Revenue Per Employee | $326,754 |
| Profits Per Employee | $33,106 |
| Employee Count | 4,000 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.73 |
Taxes
In the past 12 months, CONMED has paid $30.61 million in taxes.
| Income Tax | 30.61M |
| Effective Tax Rate | 18.77% |
Stock Price Statistics
The stock price has decreased by -24.79% in the last 52 weeks. The beta is 1.47, so CONMED's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | -24.79% |
| 50-Day Moving Average | 68.88 |
| 200-Day Moving Average | 70.21 |
| Relative Strength Index (RSI) | 33.23 |
| Average Volume (20 Days) | 537,764 |
Short Selling Information
The latest short interest is 846,967, so 2.74% of the outstanding shares have been sold short.
| Short Interest | 846,967 |
| Short Previous Month | 1.02M |
| Short % of Shares Out | 2.74% |
| Short % of Float | 2.76% |
| Short Ratio (days to cover) | 6.57 |
Income Statement
In the last 12 months, CONMED had revenue of $1.31 billion and earned $132.42 million in profits. Earnings per share was $4.25.
| Revenue | 1.31B |
| Gross Profit | 733.03M |
| Operating Income | 159.28M |
| Pretax Income | 123.90M |
| Net Income | 132.42M |
| EBITDA | 229.74M |
| EBIT | 159.28M |
| Earnings Per Share (EPS) | $4.25 |
Balance Sheet
The company has $24.46 million in cash and $947.16 million in debt, giving a net cash position of -$922.70 million or -$29.85 per share.
| Cash & Cash Equivalents | 24.46M |
| Total Debt | 947.16M |
| Net Cash | -922.70M |
| Net Cash Per Share | -$29.85 |
| Equity (Book Value) | 962.68M |
| Book Value Per Share | 31.15 |
| Working Capital | 361.88M |
Cash Flow
In the last 12 months, operating cash flow was $166.97 million and capital expenditures -$13.08 million, giving a free cash flow of $153.88 million.
| Operating Cash Flow | 166.97M |
| Capital Expenditures | -13.08M |
| Free Cash Flow | 153.88M |
| FCF Per Share | $4.98 |
Margins
Gross margin is 56.08%, with operating and profit margins of 12.19% and 10.13%.
| Gross Margin | 56.08% |
| Operating Margin | 12.19% |
| Pretax Margin | 12.47% |
| Profit Margin | 10.13% |
| EBITDA Margin | 17.58% |
| EBIT Margin | 12.19% |
| FCF Margin | 11.77% |
Dividends & Yields
This stock pays an annual dividend of $0.80, which amounts to a dividend yield of 1.31%.
| Dividend Per Share | $0.80 |
| Dividend Yield | 1.31% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 18.82% |
| Buyback Yield | 1.26% |
| Shareholder Yield | 2.57% |
| Earnings Yield | 7.01% |
| FCF Yield | 8.14% |
Analyst Forecast
The average price target for CONMED is $77.20, which is 26.29% higher than the current price. The consensus rating is "Buy".
| Price Target | $77.20 |
| Price Target Difference | 26.29% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on September 10, 2001. It was a forward split with a ratio of 1.5:1.
| Last Split Date | Sep 10, 2001 |
| Split Type | Forward |
| Split Ratio | 1.5:1 |
Scores
CONMED has an Altman Z-Score of 2.36 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.36 |
| Piotroski F-Score | 8 |